Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

 Breaking News
  • No posts were found

Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

December 04
17:00 2023
Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad,  Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

DelveInsight’s, “Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Psoriasis Pipeline Report

  • DelveInsight’s Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.
  • The leading companies working in the Psoriasis Market include Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
  • Promising Psoriasis Pipeline Therapies in the various stages of development include GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.
  • October 2023: Mylan Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Humira 40 MG in Prefilled Syringe. A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between Subjects Receiving Humira® Pre Filled Syringe (40 mg) Continuously and Subjects Undergoing Repeated Switches Between Humira® Pre Filled Syringe (40 mg) and Hulio Pre-filled Syringe (40 mg).
  • September 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for BMS-986165. The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

 

Request a sample and discover the recent advances in Psoriasis Treatment Drugs @ Psoriasis Infection Pipeline Outlook Report

 

In the Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Psoriasis Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis.

 

Find out more about Psoriasis Treatment Landscape @ Drugs for Psoriasis Treatment

 

Psoriasis Emerging Drugs Profile

  • Topical roflumilast: Arcutis Biotherapeutics
  • GSK2982772: GlaxoSmithKline

 

Psoriasis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Psoriasis. The Psoriasis companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.

 

DelveInsight’s Psoriasis pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

The Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Psoriasis Pipeline Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging Psoriasis Pipeline Therapies @ Psoriasis Clinical Trials Assessment

 

Scope of the Psoriasis Pipeline Report

  • Coverage- Global
  • Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
  • Psoriasis Pipeline Therapies- GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.

 

Dive deep into rich insights for new drugs for Psoriasis treatment, Visit @ Psoriasis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Psoriasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Psoriasis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Psoriasis Collaboration Deals
  9. Late Stage Products (Phase III)
  10. CT-P43: Celltrion
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. EDP1815: Evelo Biosciences
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. AZD0284: AstraZeneca
  17. Drug profiles in the detailed report…..
  18. Early Stage Products (Preclinical)
  19. AZD0284: AstraZeneca
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Psoriasis Key Companies
  23. Psoriasis Key Products
  24. Psoriasis- Unmet Needs
  25. Psoriasis- Market Drivers and Barriers
  26. Psoriasis- Future Perspectives and Conclusion
  27. Psoriasis Analyst Views
  28. Psoriasis Key Companies
  29. Appendix

 

For further information on the Psoriasis pipeline therapeutics, reach out @ Psoriasis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/kawasaki-disease-market

Related Articles

Categories